- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Commercialization
IU medical school's push to launch startups bears fruit
April 13, 2013
J.K. WallThe Indiana University School of Medicine has launched 12 companies in the past 18 months—a burst of startup activity
the school has never seen before.
MorePence wants $1.5M a year for life sciences institute
January 21, 2013
J.K. WallThe Indiana Applied Research Enterprise already has received support from John Lechleiter, CEO of Indianapolis-based Eli Lilly
and Co., as a place for collaboration between academic and industrial scientists.
MoreVC funds hope to help early-stage life sciences firms
December 1, 2012
J.K. WallEarly-stage venture capital has been harder and harder to come by for life sciences companies in recent years, but two Indianapolis
investors are working to raise sizable funds to help fill the gap.
MoreCommunity to commercialize innovations
November 5, 2012
J.K. WallCommunity Health Network thinks it can help patients, engage doctors and maybe even make some money by trying to turn ideas
within its organization into commercial products, service and companies.
MoreLilly CEO calls for life sciences research institute
October 23, 2012
J.K. WallEli Lilly CEO John Lechleiter on Tuesday called for creation of a "world-class" research institute in Indianapolis to bring
together scientists from universities and corporations to develop new medical therapies and companies.
MoreNext up for Indiana biotech: Feed the world
August 6, 2012
J.K. WallEven though the potential payoff for health care innovation is less certain these days, the business case for new ways to
produce more food has never been stronger. That’s the analysis that lies behind BioCrossroads' new report an agricultural
innovation.
MoreIndiana life sciences companies rethink innovation
July 28, 2012
J.K. WallResearch and development comes under pressure in an age of austerity.
MoreBioCrossroads has stoked state's life sciences industry, but challenges remain
February 11, 2012
J.K. WallIn the 10 years BioCrossroads has been promoting life sciences in Indiana, the effort has netted more than 330 new companies,
an infusion of more than $330 million in venture capital, a tripling of exports, and a growing number of mentions in national
reports on life sciences.
MorePurdue hopes center simplifies commercialization
January 30, 2012
J.K. WallPurdue University's new Innovation and Commercialization Center is supposed to be a one-stop shop for professors to get help
developing their research into products and for outside investors to find out what research is taking place there.
MoreInventor on quest to bring medical device to market
August 13, 2011
Chris O'MalleyLicensed practical nurse Nic Davis invented a device to kill and prevent the introduction of microorganisms that collect at
catheter ports.
MoreFirm joins race with IU autism drug
April 9, 2011
J.K. WallThe Indiana University School of Medicine has licensed a pediatric psychiatrist's patent on
an alcohol-dependency drug that the doctor discovered improves the language and social skills of autism patients. IU has licensed
the patent to Indianapolis-based Confluence Pharmaceuticals Inc.
MoreWishard gives IT firms in health and life sciences a place to test products
April 9, 2011
Chris O'MalleyTechPoint-led initiative is meant to help bring inventions to market by giving them a trial in real-world setting.
MoreMarcadia Biotech principals ponder next course
March 22, 2011
Chris O'MalleyMarcadia execs French, Hawryluk reflect on massive growth of Carmel firm after sale to Roche.
MoreBall State seeks leader to implement Innovation Corp. plan
March 5, 2011
Chris O'MalleyBall State University is conducting a nationwide search for a president to lead a not-for-profit it launched to boost the
commercialization of the university’s intellectual property.
MoreLife sciences to drive Purdue's next decade of building
January 26, 2011
J.K. WallOver the past 10 years, Purdue University has built Discovery Park into a thriving research and business incubation center,
launching more than 30 companies and hosting dozens more. Now Purdue will spend more than $164 million to construct a Life
and Health Sciences Quadrangle next to Discovery Park.
MoreFormer IU tech-transfer chief: State isn't competitive enough
October 30, 2010
Norm HeikensMark Long was president of the Indiana University Research & Technology Corp., which was responsible for the university’s
tech transfer, before launching a consulting firm, Long Performance Advisors, in 2008.
MoreIU hits license jackpot; Purdue royalties surge
September 18, 2010
Chris O'MalleyIndiana University had a license or two to print money from the commercialization of its technology over the last year—and
did it ever. While Purdue University didn’t collect as much in royalties from commercialization, it pulled down record
levels of research grants.
MorePromising ethanol yeast nears market launch
June 19, 2010
Chris O'MalleyA firm that may have developed a breakthrough yeast for ethanol production has landed new investment and high-octane board
members. Two-year-old Xylogenics Inc. also says it plans to license its first bioengineered yeast later this year.
MoreIndiana Seed Fund nearing end of $6 million stash
June 5, 2010
Chris O'MalleyHaving invested in 10 companies since 2005 and with its $6 million pot of money running low, the Indiana Seed Fund is nearing
a crossroads.
MoreCancer researcher battling Semafore in court
May 29, 2010
Chris O'MalleyFormer collaborator alleges firm breached its agreement with him and refused to pay royalty income.
MoreIU targets tech-transfer gap
May 15, 2010
Kathleen McLaughlinIndiana University is showing signs that it's finally serious about translating research into commercial product, through
grants it is awarding via its $10 million Innovate Indiana Fund and by developing a computing technology mini-campus.
MoreChao exit hurts drug development industry
April 28, 2010
J.K. WallPurdue University’s decision to close the Chao Center in West Lafayette is a setback for Indiana’s effort to grow
a vibrant contract drug manufacturing sector. But it’s just the latest in a series of unexpected changes—not all
for
the worse—since Indianapolis-based BioCrossroads launched a contract drug manufacturing initiative in late 2007.
MoreMedical device startup FlowCo enlists Guidant alums
April 24, 2010
Chris O'MalleyThe upstart developer of a device to help doctors choose the right-sized stent to prop open clog-prone arteries has brought
aboard former Guidant Corp. executives, including Bill McConnell. Their regulatory and marketing expertise could help FlowCo
Inc. bring its artery-measurement
product to market as soon as 2011.
MoreAriad loses $65M patent appeal against Eli Lilly
March 22, 2010
Bloomberg NewsMonday's decision throws out a $65.2 million patent-infringement verdict won by Ariad for royalties on Lilly's osteoporosis
drug Evista and sepsis medicine Xigris.
MoreVortek Surgical moving HQ to Brownsburg, adding 60 jobs
February 18, 2010
IBJ StaffIndianapolis-based Vortek Surgical LLC will relocate to Brownsburg, expanding its headquarters, manufacturing and distribution
operations and creating more than 60 jobs in the next three years.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
"And the success of the Indiana GOP to not allow an expansion of Medicaid had nothing to do with Indiana hospitals' financial woes? Fixed that for you; editorial bias rebalanced. Seriously, there are so many things wrong with Obamacare that the only way one can view it as a success is to assume that it was designed to fail our way into a government single payor healthcare system. The system is complex, creates huge regulatory burdens and overhead and yet still does not have adequate means to control escalating health care costs. But then when you elect a 10th grade math drop out with no quantitative reasoning skills to be President of one of the world's most important economies in troubled times, you can't really be surprised by blatant stupidity.
No NIMBYs here to chase off a decent development. We don't need tons of parking and we'd happily play the role of host to a downtown Whole Foods.
Whatever you do, don't change a single thing about Broad Ripple. I want it to look just like it did in the late '70s, with 30% of the north side of Broad Ripple Avenue burned out and plenty of places to park. That's right Broad Ripple, NEVER CHANGE. Let the world pass you by, don't improve your empty, abandoned lots full of weeds. Someday someone will want to film a zombie movie here.
Hollywood could step in and make a movie about the history about this forlorn series. It could be a full celebrity cast of characters. WOW. http://www.advanceindiana.blogspot.com/2013/02/indiana-taxpayers-forced-to-pay-for.html
This shouldn't come as a shock to many. Austin is a great city, and Indy needs to take some notes. Austin invests in decent transit options, has a highly educated workforce, embraces a creative class, and --despite being the state capital-- is not micromanaged by rural and suburban legislators. Want Indy to grow? Invest in the city (i.e. spend money). Raise taxes a bit, and use the money to improve education. And keep the state legislature out of Indy the other 9 months of the year.